JP2023505756A - EphA2に特異的な二環式ペプチドリガンドおよびその使用 - Google Patents
EphA2に特異的な二環式ペプチドリガンドおよびその使用 Download PDFInfo
- Publication number
- JP2023505756A JP2023505756A JP2022531404A JP2022531404A JP2023505756A JP 2023505756 A JP2023505756 A JP 2023505756A JP 2022531404 A JP2022531404 A JP 2022531404A JP 2022531404 A JP2022531404 A JP 2022531404A JP 2023505756 A JP2023505756 A JP 2023505756A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- solution
- formulation
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940966P | 2019-11-27 | 2019-11-27 | |
| US62/940,966 | 2019-11-27 | ||
| PCT/GB2020/053026 WO2021105694A1 (en) | 2019-11-27 | 2020-11-27 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505756A true JP2023505756A (ja) | 2023-02-13 |
| JP2023505756A5 JP2023505756A5 (https=) | 2023-12-05 |
Family
ID=73854820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531404A Pending JP2023505756A (ja) | 2019-11-27 | 2020-11-27 | EphA2に特異的な二環式ペプチドリガンドおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230025916A1 (https=) |
| EP (1) | EP4065085A1 (https=) |
| JP (1) | JP2023505756A (https=) |
| KR (1) | KR20220131898A (https=) |
| CN (1) | CN114760988A (https=) |
| AU (1) | AU2020392890A1 (https=) |
| CA (1) | CA3158741A1 (https=) |
| IL (1) | IL293200A (https=) |
| MX (1) | MX2022006001A (https=) |
| WO (1) | WO2021105694A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| EP3774851A1 (en) | 2018-04-04 | 2021-02-17 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| WO2020225577A1 (en) | 2019-05-09 | 2020-11-12 | Bicycletx Limited | Bicyclic peptide ligands specific for ox40 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN115698720A (zh) * | 2020-06-12 | 2023-02-03 | 拜斯科技术开发有限公司 | 特征在于促红细胞生成素产生肝细胞受体a2(epha2)的过表达的疾病的治疗 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| AU2022328932B2 (en) * | 2021-08-17 | 2026-02-19 | Tianjin Conjustar Biologics Co., Ltd. | Polypeptide drug conjugate having novel structure and application thereof |
| WO2024248860A1 (en) * | 2023-06-01 | 2024-12-05 | Bicycletx Limited | Bicyclic peptide ligands specific for epha2 and uses thereof |
| CN121889170A (zh) * | 2023-06-01 | 2026-04-17 | 拜斯科技术开发有限公司 | 对EphA2特异的双环肽配体及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190184025A1 (en) * | 2017-12-19 | 2019-06-20 | Bicycletx Limited | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
-
2020
- 2020-11-27 MX MX2022006001A patent/MX2022006001A/es unknown
- 2020-11-27 AU AU2020392890A patent/AU2020392890A1/en active Pending
- 2020-11-27 EP EP20825161.1A patent/EP4065085A1/en active Pending
- 2020-11-27 CA CA3158741A patent/CA3158741A1/en active Pending
- 2020-11-27 KR KR1020227021780A patent/KR20220131898A/ko active Pending
- 2020-11-27 JP JP2022531404A patent/JP2023505756A/ja active Pending
- 2020-11-27 IL IL293200A patent/IL293200A/en unknown
- 2020-11-27 US US17/779,226 patent/US20230025916A1/en not_active Abandoned
- 2020-11-27 CN CN202080082789.3A patent/CN114760988A/zh active Pending
- 2020-11-27 WO PCT/GB2020/053026 patent/WO2021105694A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190184025A1 (en) * | 2017-12-19 | 2019-06-20 | Bicycletx Limited | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 |
Non-Patent Citations (2)
| Title |
|---|
| CANCER RES, vol. vol. 78, suppl 13, JPN6024042413, 2018, pages 5854, ISSN: 0005442739 * |
| SCI REP, vol. vol. 9(1), JPN6024042412, 22 February 2019 (2019-02-22), pages 2636 - 1, ISSN: 0005442740 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022006001A (es) | 2022-10-27 |
| CN114760988A (zh) | 2022-07-15 |
| US20230025916A1 (en) | 2023-01-26 |
| EP4065085A1 (en) | 2022-10-05 |
| AU2020392890A1 (en) | 2022-06-02 |
| IL293200A (en) | 2022-07-01 |
| WO2021105694A1 (en) | 2021-06-03 |
| KR20220131898A (ko) | 2022-09-29 |
| CA3158741A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505756A (ja) | EphA2に特異的な二環式ペプチドリガンドおよびその使用 | |
| JP2023526451A (ja) | ネクチン-4に特異的な二環式ペプチドリガンド及びその使用 | |
| KR20240100420A (ko) | 암을 치료하기 위한 방법 | |
| JP2024545125A (ja) | Stat3分解剤およびその使用 | |
| AU2024279019A1 (en) | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF | |
| WO2024246547A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| WO2024248859A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| JP7282045B2 (ja) | B型肝炎ウイルス感染を特徴とする肝細胞癌の治療 | |
| WO2024155790A2 (en) | Novel approach for treatment of cancer using immunomodulation | |
| EA046145B1 (ru) | Фармацевтические композиции, содержащие конъюгат, содержащий токсин и бициклический пептид, и способы их применения | |
| AU2023449926A1 (en) | Bicyclic peptide ligands specific for epha2 and uses thereof | |
| WO2025056907A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| EA047123B1 (ru) | Бициклические пептидные лиганды, специфические для нектина-4, и их применение | |
| WO2025125809A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| CN118450891A (zh) | Stat3降解物及其用途 | |
| WO2025125648A1 (en) | Bicyclic peptide complex for use in treating cancer | |
| EA043796B1 (ru) | Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231124 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241018 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241022 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250417 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250805 |